[Pharmacological treatment of lipid disorders according to present clinical studies].

Hyperlipidemia beside hypertension, diabetes mellitus and smoking, is considered as the most serious factor of atherosclerosis. Studies performed in Poland indicated that only 28% of men and 32% of women has proper lipids concentration in blood serum. In 1992 the European Atherosclerosis Society (EAS) divided hyperlipoproteinemia into three types: hypercholesterolemia, hypertriglyceridemia and mixed hyperlipidemia, and each of them into mild and significant. Starting treatment attention should be paid not only on kind of lipid disorders, degree of its intensity, but also there should be evaluated other existing risk factors. Priority in treatment of hyperlipidemia consist of patients with established coronary heart disease and other forms of atherosclerotic disease. Clinical studies of last years for example like CARE, 4S, LCAS indicated plenty of advantages of lipid-lowering therapy in this group of patients, resulting in reduction total mortality coronary mortality, and recurrent coronary events. Second group consist of patients without clinical atherosclerotic disease, with high risk category. Advantages of lipid-lowering therapy in primary prevention resulting in reduction of coronary heart disease frequency proved between others study: LRC-CPPT, Oslo Study, WOSCOPS. Another groups consist postmenopausal women, in whose estrogen replacement therapy has an effect not only on improvement of lipides parameters, but also has beneficial effect on vassals endothelium and reduces risk of heart coronary disease down to 50%. Finally, there was described also problem of hypercholesterolemia treatment in young and older patients. New trends in treatment of lipid disorders were also presented.